Developing an innovative treatment for CIAS
More than 45 million people worldwide live with schizophrenia, a severe cerebral disorder that causes auditory and visual hallucinations and paranoid delusions and affects the way people manage emotions and relate with others. There are three subtypes of symptoms: positive (visual and auditory senses are affected), negative (lower social interaction), and cognitive impairment (executive function disorders, memory and attention).
Current antipsychotic drugs address mainly the positive symptoms, but the negative symptoms and cognitive impairment still require suitable pharmacological approaches and are thus an unmet medical need. Around 75% of patients with schizophrenia suffer from Cognitive Impairment Associated with Schizophrenia (CIAS).
Iproteos’ lead candidate is a first-in-class drug that addresses CIAS through a novel mechanism of action (MoA). The drug is currently finishing Regulatory Preclinical Trials, after having demonstrated in vivo activity and no toxicity, and will enter into Phase I studies in 2019.
The prolyl oligopeptidase inhibitor IPR19 ameliorates cognitive deficits in mouse models of schizophrenia (European Neuropsychopharmacology Journal, January 2017)
IRB Barcelona BioMed Conference on "Blood Brain Barrier" (Barcelona, 2nd - 4th of November 2015)
Boulder Peptide Symposium (Denver, 28th of September - 1st of October 2015)
- 28th ECNP Congress of Applied and Translational Neuroscience (Amsterdam, 29th of August - 1st of September 2015)